Drugs & Aging

, Volume 24, Issue 9, pp 701–715

Elderly-Onset Systemic Lupus Erythematosus

Prevalence, Clinical Course and Treatment
Therapy In Practice

Abstract

Systemic lupus erythematosus is an autoimmune multi-system disease of uncertain aetiology with highly variable clinical manifestations. Women of child-bearing age are most often affected; however, ≈10–20% of cases occur in older patients. Elderly-onset lupus has been defined in various studies as onset of lupus after age 50–65 years. Menopause and changes in cellular immunity with aging may contribute to development of lupus in older adults.

Many studies suggest that the clinical and serological features of elderly-onset lupus differ from those of lupus in younger patients. Arthritis, fever, serositis, sicca symptoms, Raynaud’s syndrome, lung disease and neuropsychiatric symptoms are more common in patients with elderly-onset lupus, while malar rash, discoid lupus and glomerulonephritis are less common in elderly-onset patients compared with younger lupus patients. Most elderly-onset lupus patients have a positive anti-nuclear antibody test, but the prevalence of anti-double-stranded DNA and hypocomplementaemia is lower in elderly-onset patients than in younger patients. Rheumatoid factor, anti-Ro/Sjögren’s syndrome (SS) A and anti-La/SSB are more often positive in elderly-onset patients. The diagnosis of elderly-onset lupus may be delayed for many months: insidious onset, low prevalence and similarity to other more common disorders make the diagnosis of lupus challenging in this population.

Treatment of lupus in the elderly may be complicated by co-morbidities and increased risk of toxicities from usual treatments. Optimal management of elderly-onset lupus is empiric because of a lack of randomised controlled studies. However, the approach to treatment is similar regardless of the age of the patient.

This article discusses the prevalence, clinical course, serological features, prognosis and treatment of elderly-onset systemic lupus erythematosus.

References

  1. 1.
    Gladman D, Urowitz M. Clinical features of systemic lupus erythematosus. In: Hochberg M, Silman A, Smolen J, et al., editors. Practical rheumatology. Philadelphia (PA): Mosby, 2004: 417–37Google Scholar
  2. 2.
    Maddison PJ. Systemic lupus erythematosus in the elderly. J Rheumatol Suppl 1987; 14Suppl. 13: 182–7PubMedGoogle Scholar
  3. 3.
    Ho C, Mok C, Lau C, et al. Late onset systemic lupus erythematosus in Southern Chinese. Ann Rheum Dis 1998; 57: 437–40PubMedCrossRefGoogle Scholar
  4. 4.
    Boddaert J, Huong D, Amoura Z, et al. Late-onset systemic lupus erythematosus: a personal series of 47 patients and pooled analysis of 714 cases in the literature. Medicine 2004; 83: 348–59PubMedCrossRefGoogle Scholar
  5. 5.
    Domenech I, Aydintug R, Cervera R, et al. Systemic lupus erythematosus in 50 year olds. Postgrad Med J 1992; 68: 440–4PubMedCrossRefGoogle Scholar
  6. 6.
    Cervera R, Khamashta M, Font J, et al. Systemic lupus erythematosus: clinical and immunologic patterns of disease expression in a cohort of 1,000 patients. Medicine 1993; 72: 113–24PubMedCrossRefGoogle Scholar
  7. 7.
    Hashimoto H, Tsuda H, Hirano T, et al. Differences in clinical and immunological findings of systemic lupus erythematosus related to age. J Rheumatol 1987; 14(3): 497–501PubMedGoogle Scholar
  8. 8.
    Font J, Pallares L, Cervera R, et al. Systemic lupus erythematosus in the elderly: clinical and immunological characteristics. Ann Rheum Dis 1991; 50: 702–5PubMedCrossRefGoogle Scholar
  9. 9.
    Pu S, Luo S, Cheng H, et al. The clinical features and prognosis of lupus with disease onset at age 65 and older. Lupus 2000; 9: 96–100PubMedCrossRefGoogle Scholar
  10. 10.
    Salem B, Foad I, Sheon R, et al. Systemic lupus erythematosus in the elderly. Arch Intern Med 1972; 130: 743–6CrossRefGoogle Scholar
  11. 11.
    Catoggio L, Skinner R, Smith G, et al. Systemic lupus erythematosus in the elderly: clinical and serological characteristics. J Rheumatol 1984; 11(2): 175–81PubMedGoogle Scholar
  12. 12.
    Gossat DM, Walls RS. Systemic lupus erythematosus in later life. Med J Aust 1982; 1: 297–9PubMedGoogle Scholar
  13. 13.
    Formiga F, Moga I, Pac M, et al. Mild presentation of systemic lupus erythematosus in elderly patients assessed by SLEDAI. Lupus 1999; 8: 462–5PubMedCrossRefGoogle Scholar
  14. 14.
    Voulgari PV, Katsimbri P, Alamanos Y, et al. Gender and age differences in systemic lupus erythematosus: a study of 489 Greek patients with a review of the literature. Lupus 2002; 11: 722–9PubMedCrossRefGoogle Scholar
  15. 15.
    Hutton CW, Maddison PJ. Systemic lupus erythematosus presenting as polymyalgia rheumatica in the elderly. Ann Rheum Dis 1986; 45: 641–4PubMedCrossRefGoogle Scholar
  16. 16.
    Garcia-Carrasco M, Cervera R, Rosas J, et al. Primary Sjogrens syndrome in the elderly: clinical and immunological characteristics. Lupus 1999; 8: 20–3PubMedCrossRefGoogle Scholar
  17. 17.
    Heckman GA, Papaioannou A, Adachi JD, et al. Systemic lupus erythematosus: presenting as subacute delirium in an 82-year-old woman. J Am Geriatr Soc 2001; 49: 458–61PubMedCrossRefGoogle Scholar
  18. 18.
    Dennis MS, Byrne EJ, Bendall P. Neuropsychiatric systemic lupus erythematosus in elderly people: a case series. J Neurol Neurosurg Psychiatry 1992; 55: 1157–61PubMedCrossRefGoogle Scholar
  19. 19.
    Mok CC, Mak A, Chu WP, et al. Long-term survival of Southern Chinese patients with systemic lupus erythematosus: a prospective study of all age groups. Medicine 2005; 84: 218–24PubMedCrossRefGoogle Scholar
  20. 20.
    Bertoli AM, Alarcon GS, Calvo-Alen J, et al. Systemic lupus erythematosus in a multiethnic US cohort; clinical features, course, and outcome in patients with late-onset disease. Arthritis Rheum 2006; 54(5): 1580–7PubMedCrossRefGoogle Scholar
  21. 21.
    Sarzi-Puttini P, Atzeni F, Capsoni F, et al. Drug-induced lupus erythematosus. Autoimmunity 2005; 38(7): 507–18PubMedCrossRefGoogle Scholar
  22. 22.
    Quiceno GA, Cush JJ. Iatrogenic rheumatic syndromes in the elderly. Rheum Dis Clin North Am 2007; 33(1): 123–34PubMedCrossRefGoogle Scholar
  23. 23.
    Ruffatti A, Calligaro A, Del Ross TD, et al. Anti-double-stranded DNA antibodies in the healthy elderly: prevalence and characteristics. J Clin Immunol 1990; 10: 300–3PubMedCrossRefGoogle Scholar
  24. 24.
    Kammer GM, Mishra N. Systemic lupus erythematosus in the elderly. Rheum Dis Clin North Am 2000; 26(3): 475–92PubMedCrossRefGoogle Scholar
  25. 25.
    Katz JN, Barrett J, Liang MH, et al. Utilization of rheumatology services by the elderly. Am J Med 1998; 105: 312–8PubMedCrossRefGoogle Scholar
  26. 26.
    American College of Rheumatology Ad Hoc Committee on Systemic Lupus Erythematosus Guidelines. Guidelines for referral and management of systemic lupus erythematosus in adults. Arthritis Rheum 1999; 42: 1785–96CrossRefGoogle Scholar
  27. 27.
    Kuhn A, Herrmann M, Kleber S, et al. Accumulation of apoptotic cells in the epidermis of patients with cutaneous lupus erythematosus after ultraviolet irradiation. Arthritis Rheum 2006; 54: 939–50PubMedCrossRefGoogle Scholar
  28. 28.
    Leiba A, Amital H, Gershwin ME, et al. Diet and lupus. Lupus 2001; 10: 246–8PubMedCrossRefGoogle Scholar
  29. 29.
    Manzi S, Meilahn EN, Raire JE, et al. Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham study. Am J Epidemiol 1997; 145: 408–15PubMedCrossRefGoogle Scholar
  30. 30.
    Geier DA, Geier MR. A case-control study of serious autoimmune adverse events following hepatitis B immunization. Autoimmunity 2005; 38(4): 295–301PubMedCrossRefGoogle Scholar
  31. 31.
    Gagliese L, Melzack R. Chronic pain in elderly people. Pain 1997; 70: 3–14PubMedCrossRefGoogle Scholar
  32. 32.
    Fored CM, Ejerblad E, Lindblad P, et al. Acetaminophen, aspirin, and chronic renal failure. N Engl J Med 2001; 345(25): 1801–8PubMedCrossRefGoogle Scholar
  33. 33.
    Keating GM. Tramadol sustained-release capsules. Drugs 2006; 66(2): 223–30PubMedCrossRefGoogle Scholar
  34. 34.
    Barkin RL, Barkin SJ, Barkin DS. Pharmacotherapeutic management of pain with a focus directed at the geriatric patient. Rheum Dis Clin North Am 2007; 33(1): 1–31PubMedCrossRefGoogle Scholar
  35. 35.
    Freedman GM. Chronic pain: clinical management of common causes of geriatric pain. Geriatrics 2002; 57: 36–41PubMedGoogle Scholar
  36. 36.
    Lander SA, Wallace DJ, Weisman MH. Celecoxib for systemic lupus erythematosus: case series and literature review of the use of NSAIDs in SLE. Lupus 2002; 11: 340–7PubMedCrossRefGoogle Scholar
  37. 37.
    Østensen M, Villiger PM. Nonsteroidal anti-inflammatory drugs in systemic lupus erythematosus. Lupus 2001; 10(3): 135–9PubMedCrossRefGoogle Scholar
  38. 38.
    Wolfe MM, Lichtenstein DR, Singh G. Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs. N Engl J Med 1999; 340(24): 1888–99PubMedCrossRefGoogle Scholar
  39. 39.
    Hooper L, Brown TJ, Elliott R, et al. The effectiveness of five strategies for the prevention of gastrointestinal toxicity induced by non-steroidal anti-inflammatory drugs: systematic review. BMJ 2004; 329(7472): 948–53PubMedCrossRefGoogle Scholar
  40. 40.
    Huerta C, Castellsague J, Varas-Lorenzo C, et al. Nonsteroidal anti-inflammatory drugs and risk of ARF in the general population. Am J Kidney Dis 2005; 45(3): 531–9PubMedCrossRefGoogle Scholar
  41. 41.
    Morgan A, Clark D. CNS adverse effects of nonsteroidal antiinflammatory drugs: therapeutic implications. CNS Drugs 1998; 9: 281–90CrossRefGoogle Scholar
  42. 42.
    Solomon DH, Avorn J, Sturmer T, et al. Cardiovascular outcomes in new users of coxibs and nonsteroidal antiinflammatory drugs. Arthritis Rheum 2006; 54: 1378–89PubMedCrossRefGoogle Scholar
  43. 43.
    Esdaile JM, Abrahamowicz M, Grodzicky T, et al. Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus. Arthritis Rheum 2001; 44(10): 2331–7PubMedCrossRefGoogle Scholar
  44. 44.
    The Canadian Hydroxychloroquine Study Group. A randomized study of the effect of withdrawing hydroxychloroquine sulfate in systemic lupus erythematosus. N Engl J Med 1991; 324: 150–4CrossRefGoogle Scholar
  45. 45.
    Imboden JB. Antimalarial drugs: hydroxychloroquine (Plaquenil) and chloroquine. In: Imboden JB, Hellman DB, Stone JH, editors. Current rheumatology diagnosis and treatment. 2nd ed. New York: The McGraw-Hill Companies, Inc., 2007Google Scholar
  46. 46.
    Marmor MF, Carr RE, Easterbrook M, et al, Recommendations on screening for chloroquine and hydroxychloroqine retinopathy: a report by the American Academy of Ophthalmology. Ophthalmology 2002; 109(7): 1377–82PubMedCrossRefGoogle Scholar
  47. 47.
    Chatham WW, Kimberly RP. Treatment of lupus with corticosteroids. Lupus 2001; 10: 140–7PubMedCrossRefGoogle Scholar
  48. 48.
    Orenstein WA. Immunization. In: Goldman L, Ausiello D, editors. Cecil textbook of medicine. 22nd ed. Philadelphia (PA): W.B. Saunders Company, 2004: 64–74Google Scholar
  49. 49.
    Franco-Paredes C, Diaz-Borjon A, Senger MA, et al. The ever-expanding association between rheumatologic diseases and tuberculosis. Am J Med 2006; 119(6): 470–7PubMedCrossRefGoogle Scholar
  50. 50.
    American College of Rheumatology Ad Hoc Committee on Glucocorticoid-Induced Osteoporosis. Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis: 2001 update. Arthritis Rheum 2001; 44(7): 1496–503CrossRefGoogle Scholar
  51. 51.
    Aranow C, Ginzler EM. Treatment of constitutional symptoms, skin, joint, serositis, cardio-pulmonary, hematologic and central nervous system manifestations. In: Hochberg M, Stilman A, Smolen J, et al, editors. Practical rheumatology. Philadelphia (PA): Mosby, 2004: 439–48Google Scholar
  52. 52.
    Stein MC. Immunoregulatory drugs. In: Harris Jr ED, Budd RC, Genovese MC, et al., editors. Kelley’s textbook of rheumatology. 7th ed. St Louis (MO): Saunders, 2005: 920–39Google Scholar
  53. 53.
    Naughton MA, Battaglia E, O’Brien S, et al. Identification of thiopurine methyltransferase (TPMT) polymorphisms cannot predict myelosuppression in systemic lupus erythematosus patients taking azathioprine. Rheumatology 1999; 38: 640–4PubMedCrossRefGoogle Scholar
  54. 54.
    Abu-Shakra M, Sheenfeld Y. Azathioprine therapy for patients with systemic lupus erythematosus. Lupus 2001; 10: 152–3PubMedCrossRefGoogle Scholar
  55. 55.
    Ragab A, Gilkerson E, Myers M. The effect of 6-mer-captopurine and allopurinol on granulopoiesis. Cancer Res 1974; 34: 2246–9PubMedGoogle Scholar
  56. 56.
    Kennedy DT, Hayney MS, Lake KD. Azathioprine and allopurinol: the price of an avoidable drug interaction. Ann Pharmacother 1996; 30(9): 951–4PubMedGoogle Scholar
  57. 57.
    Ginzler EM, Dooley MA, Aranow C, et al. Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. N Engl J Med 2005; 353: 2219–28PubMedCrossRefGoogle Scholar
  58. 58.
    Krensky AM, Vincenti F, Bennett WM. Immunosuppressants, tolerogens, and immunostimulants. In: Brunton LL, editor in chief. Goodman & Gilman’s the pharmacological basis of therapeutics. 11th ed. New York: McGraw-Hill Companies, Inc., 2006: 1405–31Google Scholar
  59. 59.
    Miyauchi A, Hiramine C, Tanaka S, et al. Differential effects of a single dose of cyclophosphamide on T cell subsets of the thymus and spleen in mice flow cytofluorometry analysis. Tohoku J Exp Med 1990; 162(2): 147–67PubMedCrossRefGoogle Scholar
  60. 60.
    Austin HA, Klippel JH, Balow JE, et al. Therapy of lupus nephritis: controlled trial of prednisone and cytotoxic drugs. N Engl J Med 1986; 314: 614–9PubMedCrossRefGoogle Scholar
  61. 61.
    Van Vollenhoven DF, Morabito LM, Engleman AG, et al. Treatment of systemic lupus erythematosus with dehydroepiandrosterone: 50 patients treated up to 12 months. J Rheumatol 1998; 25: 285–9PubMedGoogle Scholar
  62. 62.
    Rauova L, Likac J, Rovensky J, et al. High-dose intravenous immunoglobulins for lupus nephritis: salvage immunomodulation. Lupus 2001; 10: 209–13PubMedCrossRefGoogle Scholar
  63. 63.
    Toubi E, Kessel A, Shoenfeld Y. High-dose intravenous immunoglobulins: an option in the treatment of systemic lupus erythematosus. Hum Immunol 2005; 66: 395–402PubMedCrossRefGoogle Scholar
  64. 64.
    Leandro MJ, Cambridge G, Edwards JC, et al. B-cell depletion in the treatment of patients with systemic lupus erythematosus: a longitudinal analysis of 24 patients. Rheumatology 2005; 44: 1542–5PubMedCrossRefGoogle Scholar
  65. 65.
    Dorner T, Kaufman J, Wegener WA, et al. Initial clinical trial of epratuzumab (humanized anti-CD22 antibody) for immunotherapy of systemic lupus erythematosus. Arthritis Res Ther 2006; 8: R74PubMedCrossRefGoogle Scholar
  66. 66.
    Dooley MA, Ginzler EM. Newer therapeutic approaches for systemic lupus erythematosus: immunosuppressive agents. Rheum Dis Clin North Am 2006; 32: 91–102PubMedCrossRefGoogle Scholar
  67. 67.
    Fenton DA, Black MM. Low-dose dapsone in the treatment of subacute cutaneous lupus erythematosus. Clin Exp Dermatol 1986; 11(1): 102–3PubMedCrossRefGoogle Scholar
  68. 68.
    Neri R, Mosca M, Bernacchi E, et al. A case of SLE with acute, subacute and chronic cutaneous lesions successfully treated with dapsone. Lupus 1999; 8: 240–3PubMedCrossRefGoogle Scholar
  69. 69.
    Bottomley WW, Goodfield M. Methotrexate for the treatment of severe mucocutaneous lupus erythematosus. Br J Dermatol 1995; 133(2): 311–4PubMedCrossRefGoogle Scholar
  70. 70.
    Bezerra EL, Vilar MJ, da Trindade Neto PB, et al. Double-blind randomized, controlled clinical trial of clofazimine compared with chloroquine in patients with systemic lupus erythematosus. Arthritis Rheum 2005; 52(10): 3073–8PubMedCrossRefGoogle Scholar
  71. 71.
    Stevens RJ, Andujar C, Edwards CJ, et al. Thalidomide in the treatment of the cutaneous manifestations of lupus erythematosus: experience in sixteen consecutive patients. Br J Rheum 1997; 36: 353–9CrossRefGoogle Scholar
  72. 72.
    Duong DJ, Spigal T, Moxley RT, et al. American experience with low-dose thalidomide therapy for severe cutaneous lupus erythematosus. Arch Dermatol 1999; 135: 1079–87PubMedCrossRefGoogle Scholar
  73. 73.
    Kyriakis KP, Kontochristopoulos GJ, Panteleos DN. Experience with low-dose thalidomide therapy in chronic discoid lupus erythematosus. Int J Dermatol 2000; 39: 218–22PubMedCrossRefGoogle Scholar
  74. 74.
    Cuadrado MJ, Karim Y, Sanna G, et al. Thalidomide for the treatment of resistant cutaneous lupus: efficacy and safety of different therapeutic regimens. Am J Med 2005; 118(3): 246–50PubMedCrossRefGoogle Scholar
  75. 75.
    Houssiau A, Vasconcelos C, D’Cruz D, et al. Early response to immunosuppressive therapy predicts good renal outcome in lupus nephritis: lessons from the long-term follow-up of the Euro-Lupus Nephritis Trial. Arthritis Rheum 2004; 50(12): 3934–40PubMedCrossRefGoogle Scholar
  76. 76.
    Haney JG. Neuropsychiatric lupus. Rheum Dis Clin North Am 2005; 31: 273–98CrossRefGoogle Scholar
  77. 77.
    Sanna G, Bertolaccini ML, Mathieu A. Central nervous system lupus: a clinical approach to therapy. Lupus 2003; 12: 935–42PubMedCrossRefGoogle Scholar
  78. 78.
    Neuwelt CM, Lacks S, Kaye BR, et al. Role of intravenous cyclophosphamide in the treatment of severe neuropsychiatric systemic lupus erythematosus. Am J Med 1995; 98: 32–41PubMedCrossRefGoogle Scholar
  79. 79.
    Mok CC, Lau CS, Wong RWS. Treatment of lupus psychosis with oral cyclophosphamide followed by azathioprine maintenance: an open-label study. Am J Med 2003; 115: 59–62PubMedCrossRefGoogle Scholar
  80. 80.
    Stojanovich L, Stojanovich R, Kostich V, et al. Neuropsychiatric lupus favourable response to low dose i.v. cyclophosphamide and prednisolone (pilot study). Lupus 2003; 12: 3–7PubMedCrossRefGoogle Scholar
  81. 81.
    Ramos-Casals M, Garcia-Carrasco M, Brito MP, et al. Autoimmunity and geriatrics: clinical significance of autoimmune manifestations in the elderly. Lupus 2003; 12: 341–55PubMedCrossRefGoogle Scholar
  82. 82.
    Chakravarty KK, Al-Hillawi AH, Byron MA, et al. Anticardiolipin antibody associated ischaemic strokes in elderly patients without systemic lupus erythematosus. Age Ageing 1990; 19(2): 114–8PubMedCrossRefGoogle Scholar
  83. 83.
    Piette J-C, Cacoub P. Antiphospholipid syndrome in the elderly: caution. Circulation 1998; 97: 2195–6PubMedCrossRefGoogle Scholar
  84. 84.
    Giannouli S, Voulgarelis M, Ziakas P, et al. Anaemia in systemic lupus erythematosus: from pathophysiology to clinical assessment. Ann Rheum Dis 2006; 65(2): 144–8PubMedCrossRefGoogle Scholar
  85. 85.
    Gomard-Mennesson E, Ruivard M, Koenig M, et al. Treatment of isolated severe immune hemolytic anaemia associated with systemic lupus erythematosus: 26 cases. Lupus 2006; 15: 223–31PubMedCrossRefGoogle Scholar
  86. 86.
    Alba P, Karim MY, Hunt BJ. Mycophenolate mofetil as a treatment for autoimmune haemolytic anaemia in patients with systemic lupus erythematosus and antiphospholipid syndrome. Lupus 2003; 12: 633–5PubMedCrossRefGoogle Scholar
  87. 87.
    Mak A, Mok CC. Mycophenolate mofetil for refractory haemolytic anemia in systemic lupus erythematosus. Lupus 2005; 14(10): 856–8PubMedCrossRefGoogle Scholar
  88. 88.
    Wang SW, Cheng TT. Systemic lupus erythematosus with refractory hemolytic anemia effectively treated with cyclosporine A: a case report. Lupus 2005; 14(6): 483–5PubMedCrossRefGoogle Scholar
  89. 89.
    Erdozain JG, Ruiz-Irastorza G, Egurbide MV, et al. Sustained response to rituximab of autoimmune hemolytic anemia associated with antiphospholipid syndrome. Haematologica 2004; 89(9): ECR34PubMedGoogle Scholar
  90. 90.
    Gomard-Mennesson E, Ruivard M, Koenig M, et al. Treatment of isolated severe immune hemolytic anaemia associated with systemic lupus erythematosus: 26 cases. Lupus 2006; 15(4): 223–31PubMedCrossRefGoogle Scholar
  91. 91.
    Euler HH, Harten P, Zeuner RA, et al. Recombinant human granulocyte colony stimulating factor in patients with systemic lupus erythematosus associated neutropenia and refractory infections. J Rheumatol 1997; 24: 2153–7PubMedGoogle Scholar
  92. 92.
    Amal C, Piette JC, Leone J, et al. Treatment of severe immune thrombocytopenia associated with systemic lupus erythematosus: 59 cases. J Rheumatol 2002; 29: 75–83Google Scholar
  93. 93.
    You YN, Tefferi A, Nagorney DM. Outcome of splenectomy for thrombocytopenia associated with systemic lupus erythematosus. Ann Surg 2004; 240: 286–92PubMedCrossRefGoogle Scholar
  94. 94.
    Quartuccio L, Sacco S, Franzolini N, et al. Efficacy of cyclosporine-A in the long-term management of thrombocytopenia associated with systemic lupus erythematosus. Lupus 2006; 15: 76–9PubMedCrossRefGoogle Scholar
  95. 95.
    Moss C, Hamilton PJ. Thrombocytopenia in systemic lupus erythematosus responsive to dapsone. BMJ 1988; 297: 266PubMedCrossRefGoogle Scholar
  96. 96.
    Vasoo S, Thumboo J, Fong KY. Refractory immune thrombocytopenia in systemic lupus erythematosus: response to mycophenolate mofetil. Lupus 2003; 12: 630–2PubMedCrossRefGoogle Scholar
  97. 97.
    Al-Hashimi I. Xerostomia secondary to Sjogren’s syndrome in the elderly: recognition and management. Drugs Aging 2005; 22(11): 887–99PubMedCrossRefGoogle Scholar
  98. 98.
    Block JA, Sequeira W. Raynaud’s phenomenon. Lancet 2001; 357: 2042–8PubMedCrossRefGoogle Scholar
  99. 99.
    Fries R, Shariat K, von Wilmowsky H, et al. Sildenafil in the treatment of Raynaud’s phenomenon resistant to vasodilatory therapy. Circulation 2005; 112: 2980–5PubMedGoogle Scholar

Copyright information

© Adis Data Information BV 2007

Authors and Affiliations

  1. 1.Department of Medicine, Division of RheumatologySUNY Downstate Medical CenterBrooklynUSA
  2. 2.Department of Medicine, Section of RheumatologyVA-New York Harbor Healthcare SystemBrooklynUSA
  3. 3.Medical Service (III)VA-New York Harbor Healthcare SystemBrooklyn, New YorkUSA

Personalised recommendations